EMD 87580
( DrugBank: - / KEGG DRUG: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
113 | 筋ジストロフィー | 4 |
113. 筋ジストロフィー
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
Showing 1 to 4 of 4 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2015-002530-50-IT (EUCTR) | 19/01/201720170119 | 22/08/201820180822 | A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of rimeporide in patients with Duchenne Muscular Dystrophy (DMD) A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodyna ... | A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of rimeporide in patients with Duchenne Muscular Dystrophy (DMD) - RIM4DMD A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodyna ... | Distrofia Muscolare di Duchenne (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Distrofia Muscolare di Duchenne (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Te ... | Product Name: rimeporide Product Code: EMD 87580 | ESPERARE FOUNDATION | NULL | Not Recruiting | Female: no Male: yes | 20 | Phase 1 | France;Spain;United Kingdom;Italy | ||
2 | EUCTR2015-002530-50-FR (EUCTR) | 18/12/201520151218 | 11/09/201520150911 | Rimeporide in patients with Duchenne Muscular Dystrophy | A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy. A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodyna ... | Duchenne Muscular Dystrophy (DMD) MedDRA version: 18.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Duchenne Muscular Dystrophy (DMD) MedDRA version: 18.0;Level: PT;Classification code 10013801;Term: ... | Product Name: Rimeporide Product Code: EMD 87580 INN or Proposed INN: N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate Other descriptive name: Rimeporide INN or Proposed INN: N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate Other descriptive name: Rimeporide Product Name: Rimeporide Product Code: EMD 87580 INN or Proposed INN: N-(4,5-Bis methanesulfonyl-2-met ... | EspeRare | NULL | Not Recruiting | Female: no Male: yes | 20 | Phase 1 | France;Spain;Italy;United Kingdom;Switzerland | ||
3 | EUCTR2015-002530-50-ES (EUCTR) | 04/11/201520151104 | 25/08/201520150825 | Rimeporide in patients with Duchenne Muscular Dystrophy | A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy. - Rim4DMD A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodyna ... | Duchenne Muscular Dystrophy (DMD) MedDRA version: 18.1;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Duchenne Muscular Dystrophy (DMD) MedDRA version: 18.1;Level: PT;Classification code 10013801;Term: ... | Product Name: Rimeporide Product Code: EMD 87580 INN or Proposed INN: N(4,5Bis methanesulfonyl2methylbenzoyl) guanidine hydrochloride monohydrate Other descriptive name: Rimeporide Product Name: Rimeporide Product Code: EMD 87580 INN or Proposed INN: N(4,5Bis methanesulfonyl2methylb ... | EspeRare | NULL | Not Recruiting | Female: no Male: yes | 20 | Phase 1 | France;Spain;Italy;United Kingdom;Switzerland | ||
4 | EUCTR2015-002530-50-GB (EUCTR) | 29/10/201520151029 | 07/09/201520150907 | Rimeporide in patients with Duchenne Muscular Dystrophy | A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy - RIM4DMD A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodyna ... | Duchenne Muscular Dystrophy (DMD) MedDRA version: 18.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Duchenne Muscular Dystrophy (DMD) MedDRA version: 18.0;Level: PT;Classification code 10013801;Term: ... | Product Name: Rimeporide Product Code: EMD 87580 INN or Proposed INN: N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate Other descriptive name: Rimeporide INN or Proposed INN: N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate Other descriptive name: Rimeporide Product Name: Rimeporide Product Code: EMD 87580 INN or Proposed INN: N-(4,5-Bis methanesulfonyl-2-met ... | EspeRare | NULL | Not Recruiting | Female: no Male: yes | 20 | Phase 1 | France;Spain;Italy;Switzerland;United Kingdom |